IbogaBaseThe Iboga Evidence Base
Clinical boundary Schedule I in the U.S. Serious cardiac risk Not FDA-approved No dosing or referrals Schedule I · cardiac risk Not FDA-approved · no referrals

Evidence

Depression and mood symptoms

LAST REVIEWED 2026-05-18 · 346 SOURCES · 0 CORRECTIONS

Mood improvements appear in some Ibogaine-related observational and veteran studies, usually as secondary outcomes.

Confidence: ModerateSource type: Study
Evidence level
secondary outcomes and small reports
Sample sizes
Small cohorts and case-level reports dominate the public literature.
Design quality
Depression-specific controlled Ibogaine evidence remains limited.
Outcomes
Depression scale changes, quality of life, suicidality, sleep, and substance-use outcomes must be separated.
Limitations
Expectation effects, concurrent treatment, post-acute recovery, integration, and regression to the mean can affect mood measures.
Safety signals
Suicidality, bipolar disorder, psychosis risk, serotonergic medications, sleep disruption, and cardiac risk.
What is not proven
Ibogaine is not proven as a depression treatment.
Best next source
2026 psychiatric scoping review and condition-specific controlled trials if they appear.